Improving CKD Diagnosis and Treatment Rates Through Support Programs in Primary Care Settings: A Scientific Approach to Investigating a Multi-Channel Support Program to Improve CKD Diagnosis and Management in Primary Care. (Phase 1)

Improving CKD Diagnosis and Treatment Rates Through Support Programs in Primary Care Settings. - CKD Support Program Implementation Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000061950

Enrollment

200

Registered

2026-06-18

Start date

2026-06-18

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease (CKD)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -PCPs practicing at a clinic in Japan. -PCPs registered on the nationwide M3 platform. -PCPs having opportunities to diagnose and treat patients with CKD.

Exclusion criteria

Exclusion criteria: PCPs self-reporting their primary specialty in any fields other than the designated internal medicine subspecialties, which include general internal medicine, cardiology, gastroenterology, respiratory medicine, diabetes/endocrinology and metabolism, rheumatology/collagen disease, and allergy.

Design outcomes

Primary

Measure	Time frame
Level of knowledge and awareness -Recognition of CKD diagnostic definitions -Recognition of CKD referral criteria -Awareness of CKD risk factors -Perception of useful indicators/tests for recognizing CKD -Recognition of the indications for SGLT2 inhibitors and Mineralocorticoid receptor antagonists (MRAs) in CKD and diabetic kidney disease Barriers and needs -Perceived barriers to performing blood tests for CKD diagnosis -Perceived barriers to performing urine tests for CKD diagnosis -Information and support needs as a primary care physician regarding CKD diagnosis and treatment	—

Measure

Time frame

Level of knowledge and awareness -Recognition of CKD diagnostic definitions -Recognition of CKD referral criteria -Awareness of CKD risk factors -Perception of useful indicators/tests for recognizing CKD -Recognition of the indications for SGLT2 inhibitors and Mineralocorticoid receptor antagonists (MRAs) in CKD and diabetic kidney disease Barriers and needs -Perceived barriers to performing blood tests for CKD diagnosis -Perceived barriers to performing urine tests for CKD diagnosis -Information and support needs as a primary care physician regarding CKD diagnosis and treatment

—

Secondary

Measure	Time frame
Screening frequency for at-risk patients: -Frequency of blood tests (serum creatinine, eGFR) for patients with CKD risk factors -Frequency of urine tests (urine albumin-to-creatinine ratio, urine protein-to-creatinine ratio, qualitative proteinuria) for patients with CKD risk factors -Monitoring frequency for diagnosed patients -Frequency of blood tests for patients recognized as having CKD Treatment status -Utilization of specific medications for CKD patients with comorbid diabetes mellitus or albuminuria/proteinuria Status of guideline engagement -Awareness of the "Clinical practice guidebook for diagnosis and treatment of chronic kidney disease 2024" and "Evidence-based clinical practice guideline for CKD 2023" -Possession status of the "Clinical practice guidebook for diagnosis and treatment of chronic kidney disease 2024" -Reasons for non-possession of the "Clinical practice guidebook for diagnosis and treatment of chronic kidney disease 2024" Clinical practice and attitudes -Self-confidence in CKD management -Recognition of the necessity to evaluate renal function in at-risk patients -Disease naming conventions used for registration -Implementation status of specific checks/confirmations for patients diagnosed with CKD	—

Measure

Time frame

Screening frequency for at-risk patients: -Frequency of blood tests (serum creatinine, eGFR) for patients with CKD risk factors -Frequency of urine tests (urine albumin-to-creatinine ratio, urine protein-to-creatinine ratio, qualitative proteinuria) for patients with CKD risk factors -Monitoring frequency for diagnosed patients -Frequency of blood tests for patients recognized as having CKD Treatment status -Utilization of specific medications for CKD patients with comorbid diabetes mellitus or albuminuria/proteinuria Status of guideline engagement -Awareness of the "Clinical practice guidebook for diagnosis and treatment of chronic kidney disease 2024" and "Evidence-based clinical practice guideline for CKD 2023" -Possession status of the "Clinical practice guidebook for diagnosis and treatment of chronic kidney disease 2024" -Reasons for non-possession of the "Clinical practice guidebook for diagnosis and treatment of chronic kidney disease 2024" Clinical practice and attitudes -Self-confidence in CKD management -Recognition of the necessity to evaluate renal function in at-risk patients -Disease naming conventions used for registration -Implementation status of specific checks/confirmations for patients diagnosed with CKD

—

Countries

Japan

Contacts

Public ContactYuta Asanuma

Mebix, Inc. Research Promotion Division

Implementation_Study_Support@mebix.co.jp03-4362-4504

Outcome results